These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31401098)

  • 1. Trastuzumab Cardiotoxicity After Anthracycline Exposure Constitutes a Complex and Clinically Important Entity.
    Ewer MS; Ewer SM
    JACC Heart Fail; 2019 Sep; 7(9):805-807. PubMed ID: 31401098
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardio-oncology: the Nuclear Option.
    Alvarez JA; Russell RR
    Curr Cardiol Rep; 2017 Apr; 19(4):31. PubMed ID: 28315122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
    Hamirani Y; Fanous I; Kramer CM; Wong A; Salerno M; Dillon P
    Med Oncol; 2016 Jul; 33(7):82. PubMed ID: 27334792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?
    Zheng H; Mahmood SS; Khalique OK; Zhan H
    JCO Oncol Pract; 2024 Aug; 20(8):1055-1063. PubMed ID: 38662969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
    de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System.
    Moriyama S; Fukata M; Kusaba H; Maruyama T; Akashi K
    Heart Fail Clin; 2020 Apr; 16(2):231-241. PubMed ID: 32143767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
    Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
    Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Levis BE; Binkley PF; Shapiro CL
    Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure and chemotherapeutic agents.
    Piper S; McDonagh T
    Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.